Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 12:09 pm IST
Share
Kyung Dong Pharmaceutical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 41,328.14 million compared to KRW 40,294.2 million a year ago. Net loss was KRW 1,262.15 million compared to KRW 1,206.07 million a year ago. Basic loss per share from continuing operations was KRW 47 compared to KRW 44 a year ago. Basic loss per share was KRW 47 compared to KRW 44 a year ago.
For the six months, sales was KRW 78,855.76 million compared to KRW 87,431.1 million a year ago. Net loss was KRW 1,753.96 million compared to net income of KRW 2,041.2 million a year ago. Basic loss per share from continuing operations was KRW 65 compared to basic earnings per share from continuing operations of KRW 75 a year ago. Basic loss per share was KRW 65 compared to basic earnings per share of KRW 75 a year ago.
KYUNG DONG PHARMACEUTICAL CO.,LTD. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Companyâs products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. It also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
KYUNG DONG PHARMACEUTICAL CO., LTD. 
